Pedal the cause
Join us September 19-20, 2026
Join the St. Louis Children’s Hospital Pedal the Cause team and help raise funds for critical cancer research, bringing us all closer to the day we live in a world without this disease. Every dollar we raise through Pedal the Cause remains in St. Louis, funding research at Siteman Kids at St. Louis Children’s Hospital and Siteman Cancer Center.
Siteman Kids seeks to advance pediatric cancer research and improve outcomes for kids and their families. Through funding from vital partners like Pedal the Cause, St. Louis Children’s Hospital Foundation and the Children’s Discovery Institute (CDI), we are enabling researchers to discover lifesaving treatments and cures for pediatric cancers.
St. Louis Children’s Hospital Team Captains
Trish Lollo, hospital president
Dr. Gary Silverman, pediatrician-in-chief
Dr. Jorge Di Paola, division chief, pediatric hematology-oncology
For more information about St. Louis Children’s Hospital’s Pedal The Cause Team, please contact Megan Perez at [email protected]
Check out the St. Louis Children’s Hospital Team jersey
MEET THE 2025 PEDAL THE CAUSE AMBASSADOR, HENRY
Henry, a spirited third grader, is full of curiosity and kindness and doesn’t know a stranger. His days are filled with adventures such as reading “Dog Man” or mastering a ninja warrior course, all while fueling up on his favorite foods—tacos and donuts. You would never guess that Henry has been on a unique journey with Neurofibromatosis Type 1 (NF1) since birth. NF1 is a genetic condition characterized by light brown patches on the skin and benign nerve tumors that develop on or under the skin. Brain tumors are also known to occur in children and adults with NF1, so Henry has been monitored regularly at Siteman Kids at St. Louis Children’s Hospital since his diagnosis at 8 months old.
When Henry was 4 years old, he began to lose his vision. It soon was discovered that an inoperable tumor was intertwined with his optic nerve. Because of the research being done right here in St. Louis, Henry’s team was able to offer a new care option, targeted therapy known as a MEK inhibitor and oral chemotherapy drugs, and his tumor began to shrink and his vision improved. Thanks to donor support, these studies drive research forward to ultimately give kids with brain tumors the chance to live healthy lives.